Collegium Pharmaceutical Analyst Ratings
Collegium Pharmaceutical Analyst Ratings
While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Collegium Pharmaceutical (COLL) is trading at is $24.70, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/04/2023 | — | HC Wainwright & Co. | Reiterates | → Neutral | |
| 08/04/2023 | 41.7% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/30/2023 | 41.7% | Needham | → $35 | Reiterates | Buy → Buy |
| 05/05/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 05/02/2023 | 21.46% | Jefferies | → $30 | Assumes | → Buy |
| 04/19/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 02/24/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 02/08/2023 | 41.7% | Needham | → $35 | Reiterates | → Buy |
| 01/05/2023 | 41.7% | Needham | $34 → $35 | Maintains | Buy |
| 11/04/2022 | 37.65% | Needham | $36 → $34 | Maintains | Buy |
| 08/08/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/06/2022 | 45.75% | Needham | $34 → $36 | Maintains | Buy |
| 02/22/2022 | 70.04% | Piper Sandler | $36 → $42 | Maintains | Overweight |
| 02/15/2022 | 17.41% | HC Wainwright & Co. | $26 → $29 | Maintains | Buy |
| 02/15/2022 | 37.65% | Needham | $28 → $34 | Maintains | Buy |
| 11/15/2021 | 13.36% | Needham | $26 → $28 | Maintains | Buy |
| 11/05/2021 | 5.26% | Needham | $32 → $26 | Maintains | Buy |
| 08/06/2021 | -10.93% | Cantor Fitzgerald | $30 → $22 | Downgrades | Overweight → Neutral |
| 08/06/2021 | 29.55% | Needham | $34 → $32 | Maintains | Buy |
| 08/06/2021 | 13.36% | HC Wainwright & Co. | $33 → $28 | Maintains | Buy |
| 01/11/2021 | 33.6% | HC Wainwright & Co. | $29 → $33 | Maintains | Buy |
| 11/09/2020 | 17.41% | HC Wainwright & Co. | $31 → $29 | Maintains | Buy |
| 07/14/2020 | -67.61% | BWS Financial | → $8 | Initiates Coverage On | → Sell |
| 05/27/2020 | — | Guggenheim | Initiates Coverage On | → Neutral | |
| 05/08/2020 | 45.75% | Needham | $38 → $36 | Maintains | Buy |
| 02/12/2020 | 41.7% | Piper Sandler | $27 → $35 | Maintains | Overweight |
| 02/07/2020 | 21.46% | Cantor Fitzgerald | $24 → $30 | Maintains | Overweight |
| 02/07/2020 | 53.85% | Needham | $36 → $38 | Maintains | Buy |
| 01/08/2020 | 45.75% | Needham | $28 → $36 | Maintains | Hold |
| 08/08/2019 | -2.83% | Cantor Fitzgerald | $35 → $24 | Reiterates | → Overweight |
| 05/03/2019 | -6.88% | HC Wainwright & Co. | → $23 | Assumes | → Buy |
| 04/12/2019 | — | Janney Montgomery Scott | Assumes | → Buy | |
| 03/20/2019 | -10.93% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 08/09/2018 | 41.7% | Cantor Fitzgerald | $40 → $35 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/04/2023 | - | HC Wainwright公司 | 重申 | →中性 | |
| 08/04/2023 | 41.7% | 李约瑟 | →$35 | 重申 | 购买→购买 |
| 2023年05月30日 | 41.7% | 李约瑟 | →$35 | 重申 | 购买→购买 |
| 05/05/2023 | 41.7% | 李约瑟 | →$35 | 重申 | →购买 |
| 05/02/2023 | 21.46% | 杰富瑞 | →$30 | 假设 | →购买 |
| 04/19/2023 | 41.7% | 李约瑟 | →$35 | 重申 | →购买 |
| 02/24/2023 | 41.7% | 李约瑟 | →$35 | 重申 | →购买 |
| 02/08/2023 | 41.7% | 李约瑟 | →$35 | 重申 | →购买 |
| 01/05/2023 | 41.7% | 李约瑟 | $34→$35 | 维护 | 买 |
| 11/04/2022 | 37.65% | 李约瑟 | $36→$34 | 维护 | 买 |
| 2022/08/08 | - | HC Wainwright公司 | 评级下调 | 购买→中性 | |
| 04/06/2022 | 45.75% | 李约瑟 | $34→$36 | 维护 | 买 |
| 02/22/2022 | 70.04% | 派珀·桑德勒 | $36→$42 | 维护 | 超重 |
| 02/15/2022 | 17.41% | HC Wainwright公司 | $26→$29 | 维护 | 买 |
| 02/15/2022 | 37.65% | 李约瑟 | $28→$34 | 维护 | 买 |
| 2021年11月15日 | 13.36% | 李约瑟 | $26→$28 | 维护 | 买 |
| 2021年11月05日 | 5.26% | 李约瑟 | $32→$26 | 维护 | 买 |
| 08/06/2021 | -10.93% | 康托·菲茨杰拉德 | $30→$22 | 评级下调 | 超重→中性 |
| 08/06/2021 | 29.55% | 李约瑟 | $34→$32 | 维护 | 买 |
| 08/06/2021 | 13.36% | HC Wainwright公司 | $33→$28 | 维护 | 买 |
| 2021/11/01 | 33.6% | HC Wainwright公司 | $29→$33 | 维护 | 买 |
| 11/09/2020 | 17.41% | HC Wainwright公司 | $31→$29 | 维护 | 买 |
| 07/14/2020 | -67.61% | BWS金融 | →$8 | 开始承保 | →销售 |
| 05/27/2020 | - | 古根海姆 | 开始承保 | →中性 | |
| 05/08/2020 | 45.75% | 李约瑟 | $38→$36 | 维护 | 买 |
| 02/12/2020 | 41.7% | 派珀·桑德勒 | $27→$35 | 维护 | 超重 |
| 02/07/2020 | 21.46% | 康托·菲茨杰拉德 | $24→$30 | 维护 | 超重 |
| 02/07/2020 | 53.85% | 李约瑟 | $36→$38 | 维护 | 买 |
| 1/08/2020 | 45.75% | 李约瑟 | $28→$36 | 维护 | 保持 |
| 2019年08月08日 | -2.83% | 康托·菲茨杰拉德 | $35→$24 | 重申 | →超重 |
| 2019年05月03日 | -6.88% | HC Wainwright公司 | →$23 | 假设 | →购买 |
| 2019年4月12日 | - | 詹尼·蒙哥马利·斯科特 | 假设 | →购买 | |
| 2019/03/20 | -10.93% | SunTrust Robinson Humphrey | →$22 | 开始承保 | →购买 |
| 2018年08月09日 | 41.7% | 康托·菲茨杰拉德 | $40→$35 | 维护 | 超重 |
What is the target price for Collegium Pharmaceutical (COLL)?
科莱姆制药公司(Colcium Pharmtics)的目标价是多少？
The latest price target for Collegium Pharmaceutical (NASDAQ: COLL) was reported by HC Wainwright & Co. on August 4, 2023. The analyst firm set a price target for $0.00 expecting COLL to fall to within 12 months (a possible -100.00% downside). 11 analyst firms have reported ratings in the last year.
纳斯达克公司(纳斯达克代码：COL)的最新目标价是由HC Wainwright&Co.于2023年8月4日报道的。这家分析公司将目标价定为0.00美元，预计Coll将在12个月内下跌(跌幅可能为-100.00%)。过去一年，有11家分析公司公布了评级。
What is the most recent analyst rating for Collegium Pharmaceutical (COLL)?
科莱姆制药公司(Coll)最近的分析师评级是多少？
The latest analyst rating for Collegium Pharmaceutical (NASDAQ: COLL) was provided by HC Wainwright & Co., and Collegium Pharmaceutical reiterated their neutral rating.
纳斯达克(代码：COL)的最新分析师评级由HC Wainwright&Co.提供，科大药业重申其中性评级。
When is the next analyst rating going to be posted or updated for Collegium Pharmaceutical (COLL)?
科莱姆制药(Coll)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Collegium Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Collegium Pharmaceutical was filed on August 4, 2023 so you should expect the next rating to be made available sometime around August 4, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与科莱姆制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Colcium Pharmtics的上一次评级是在2023年8月4日提交的，所以你应该预计下一次评级将在2024年8月4日左右的某个时候公布。
Is the Analyst Rating Collegium Pharmaceutical (COLL) correct?
分析师对科尔制药(Colcium Pharmtics)的评级正确吗？
While ratings are subjective and will change, the latest Collegium Pharmaceutical (COLL) rating was a reiterated with a price target of $0.00 to $0.00. The current price Collegium Pharmaceutical (COLL) is trading at is $24.70, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的大学制药(COL)评级被重申，目标价在0.00美元至0.00美元之间。科莱姆制药公司目前的股价为24.70美元，超出了分析师的预测范围。
